Pharma R&D Outsourcing: Strategic Imperative or Selling the Family Jewels?
Strong governance and strategic deployment can keep innovation and competitiveness high
Traditionally, most pharma firm’s value proposition has been strongly tied to its research and development (R&D) capabilities. But with industry growth predictions hovering around 1 percent over the next five years, RDO is fast becoming a necessary and strategic approach to maintaining a healthy, innovative pharma industry.
Click here to view this document.
Adobe Reader is required to view this document.
|
